Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Gains Hepatitis Market Access Through Idenix Majority Stake

Executive Summary

Novartis is adding three novel hepatitis products to its antiviral pipeline through a 51% stake in the privately held biotech company Idenix

You may also be interested in...



Idenix/Novartis Telbivudine NDA Filing Slated For Late 2005, IPO Says

Idenix plans to file an NDA for the hepatitis B therapy telbivudine in late 2005, the Cambridge-based biotech company says in an initial public offering filed with the Securities & Exchange Commission Dec. 15

Idenix/Novartis Telbivudine NDA Filing Slated For Late 2005, IPO Says

Idenix plans to file an NDA for the hepatitis B therapy telbivudine in late 2005, the Cambridge-based biotech company says in an initial public offering filed with the Securities & Exchange Commission Dec. 15

Biotech Startups Trading IPO Filings For Selling Block – BIO Panel

The goal of a biotech startup appears to have shifted away from a focus on entering the public market through an IPO in favor of building the company to become an acquisition target

UsernamePublicRestriction

Register

ID1125791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel